Science2 distinct publishers3 min readUpdated
A Nature paper reports direct positional isomerisation of pyridines by nitrogen insertion and deletion, turning what were separate syntheses for each isomer into one starting material.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
A group led by Hong Sungwoo, associate director of the Institute for Basic Science's Center for Catalytic Hydrocarbon Functionalizations and a professor at KAIST, has reported a reaction that converts a pyridine directly into its positional isomers by relocating the ring nitrogen rather than shifting the groups attached to the ring [1][2]. The work, published in Nature by Choi, Ju, Park and co-authors, matters because the isomers medicinal chemists compare during structure-activity work have until now each required their own starting material and their own route [3][6][7].
The logic is a change of reference point. A pyridine is a six-membered aromatic ring with five carbons and one nitrogen, and it is one of the most common motifs in drug molecules [4]. Positions on that ring are defined relative to the nitrogen, so moving the nitrogen changes the positional relationship of every substituent even though each substituent stays bonded to the same carbon [8]. That relationship is not cosmetic: with identical substituents, changing where they sit relative to the nitrogen can substantially alter solubility, metabolic stability and interactions with biological targets [5]. Trying to move the substituents themselves has been hard to generalise, because different functional groups want different conditions [9].
Mechanically, the team inserts a new nitrogen into the pyridine framework to make an expanded intermediate, then deletes the original nitrogen, leaving the externally supplied one in the rebuilt ring [10]. The original nitrogen departs as N2, which supplies a strong thermodynamic driving force [11]. Because the intermediates are too short-lived to isolate, the mechanism rests on labelling: nitrogen-15 reagents showed the nitrogen in the new position came from the external reagent [12][13], the original ring nitrogen was confirmed to leave as part of N2 [14], and carbon-13 labelling showed the ring carbons kept their original positions [15]. That combination is what distinguishes genuine transposition from a wholesale skeletal rearrangement [16].
Two practical details stand out. Solvent choice steers the outcome: toluene strongly favoured one positional arrangement, while more polar solvents gave different isomer mixtures, so the same substrate can be pushed toward different products [17]. And because the substituents do not have to participate in the reaction, several can change their positional relationship at once while keeping their identities and relative arrangement [18]. The reported scope covers mono-, di- and multisubstituted pyridines with a range of functional groups common in medicinal chemistry [19][20], demonstrated on complex substrates derived from menthol, sulindac, paracetamol, flurbiprofen, indomethacin and tedizolid, among others [21][22].
What the publicly visible material does not give is numbers. Neither the Nature abstract nor the release reports yields or isomer ratios [23], and the supplementary information includes a section on positional isomers and unsuccessful substrates alongside the mechanistic studies, DFT-computed mechanism and an X-ray structure for one compound [24][25]. The authors' own framing is that substitution pattern becomes a mutable variable in retrosynthetic design [26]; whether that holds depends on how narrow the unsuccessful set turns out to be.
Watch the substrate table and the regioselectivity section when the supplementary data is read in detail: the questions for a planning chemist are which isomer ratios are achievable in toluene versus polar solvent, what the nitrogen source costs at scale, and whether basic nitrogens elsewhere in a drug-like molecule survive the insertion step.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
A research team developed a molecular editing strategy that directly converts pyridine compounds into their positional isomers by relocating the nitrogen atom within the pyridine ring rather than moving individual substituents, preserving the substituents.
Pyridine is a six-membered aromatic ring containing five carbon atoms and one nitrogen atom, and is one of the most common structural motifs in pharmaceutical compounds.
Even when two pyridine molecules contain exactly the same substituents, changing where those substituents sit relative to the nitrogen atom can substantially alter properties such as solubility, metabolic stability and interactions with biological targets.
Medicinal chemists routinely compare different positional isomers when investigating structure-activity relationships, but obtaining these isomers has traditionally required separate starting materials and independently designed synthetic routes.
According to the Nature abstract, direct interconversion of pyridine positional isomers remains largely inaccessible, so each isomer is typically prepared through an independent synthesis.
Because positions around a pyridine ring are defined relative to its nitrogen atom, relocating the nitrogen changes the positional relationship of the substituents even though the substituents remain attached to the same carbon atoms.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed with mechanistic and structural backing, but key numbers not visible
The central claims rest on a peer-reviewed Nature paper whose supplementary record includes reaction optimization, substrate scope, regioselectivity studies, explicitly catalogued unsuccessful substrates, mechanistic studies with a computed mechanism and DFT data, and a CheckCIF-validated X-ray structure. Mechanism is corroborated by 15N and 13C labelling rather than asserted. The ceiling is set by access: the supplied sources expose only the abstract plus a press narrative, with no yields, isomer ratios or failure rates, and no independent replication or outside expert assessment.
No use beyond the originating laboratory reported
The supplied sources document publication and the authors' own substrate demonstrations, including three marketed drugs, but contain no evidence of any second laboratory, contract research organisation or pharmaceutical company running the transformation, no licensing, and no scale-up. Author-run demonstrations are scope evidence, not adoption, so no adoption score is assigned.
Mildly overstated: 'general' and 'practical' outrun the visible numbers
Framing is restrained by science-news standards - mechanism, isotope controls and solvent-dependence are described concretely, and the marketed-drug conversions are real reported results rather than speculation. The gap comes from unquantified generality: the abstract calls the transformation 'practical' and 'broadly applicable' and the press account foregrounds late-stage drug editing, while neither supplied source offers a yield, an isomer ratio or the failure boundary the paper itself catalogues, and no user outside the originating group exists yet. Polar solvents are noted to give isomer mixtures, a practicality caveat neither publisher pursues.
Institutional announcement plus paywalled primary source
The phys.org piece is a promotional-register institutional account of an IBS/KAIST result, naming the centre and its associate director and closing with a drug-discovery utility argument; it carries no outside chemist and no limitations section, which is the standard incentive profile of research-communications output. The journal page pairs the authors' own strongest framing with subscription and per-article purchase offers that gate the verifying data. These are ordinary publication incentives rather than evidence of commercial promotion: no funder, sponsor, patent, licensee or competing product is disclosed in either source.
Solid on what was done, unresolved on how well it works
Confidence is high that the reaction and its mechanism are as described: two sources agree, the claims are peer reviewed, and the mechanistic account is supported by isotope labelling, computation and a validated crystal structure with no contradiction anywhere in the cluster. It is held down by a thin publisher set (one primary, one institutional account, no independent expert), the absence of any quantitative performance data in the supplied material, and no adoption signal to corroborate the practicality claim.
science
A phage kinase with no target list: EMBL finds one enzyme that breaks several bacterial defences1 distinct publisher
science
HIPAA Covers Less Than You Think, And "Anonymized" Is Not A Legal Shield1 distinct publisher
product
LLNL closes a 20 percent gap in diamond melting, and stakes a fusion gain claim on it1 distinct publisher
science
Psilocybin's 'oneness' now has a brain-network correlate, and it was found by sorting people on self-report1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
nature.com
1 article · August 16, 2026
phys.org
1 article · August 18, 2026